Senator Risch to Asharq Al-Awsat: Biden Should Strengthen Partnerships to Confront Iranian Threats

Jim E Risch, US Senator for Idaho
Jim E Risch, US Senator for Idaho
TT

Senator Risch to Asharq Al-Awsat: Biden Should Strengthen Partnerships to Confront Iranian Threats

Jim E Risch, US Senator for Idaho
Jim E Risch, US Senator for Idaho

Prominent US congress members have welcomed President Joe Biden’s trip to the Middle East. Wide criticism leveled against the Biden administration for its dealing with the Iranian file turned into calls for fixing strained relations with the region’s countries.

Speaking to Asharq Al-Awsat, senior Republican in the Senate Foreign Relations Committee Jim Risch considered that Biden has a serious shortfall in his credibility, a matter which must be fixed with US partners in the Middle East.

Citing the withdrawal from Afghanistan, the promoted transition to the Indo-Pacific, the hardline policies of arms sales, and the policy with Iran that threaten the security of Washington’s partners, Risch said that Biden must reassure the region that the US will remain a reliable partner.

Risch warned that if Biden fails to do so, he risks losing the region to Russia and China.

The senator also criticized the current administration's performance, explaining that many domestic partners believe that the president’s political capital is deteriorating rapidly, and they are anxiously awaiting the next administration.

Risch voiced his fears that Biden’s visit to the Middle could be late.

According to Risch, the administration has finally begun to change course about some of its harmful policies in the Middle East, especially with regard to the Abraham Accords, but many of these steps have been delayed.

The senator emphasized that the policy with Iran remains the main sticking point.

In view of that, Risch accused the US administration of threatening the security of its allies in the Middle East with its efforts to return to the Iran nuclear deal.

The agreement is still fraught with problems, said Risch about the Iran nuclear deal.

It completely fails to address Iran's domestic terrorism and its ballistic missile program, he told Asharq Al-Awsat, adding that Tehran's efforts to provide hundreds of drones to Russia for use in Ukraine was not helping either.

After the nuclear deal was reached in 2015, sanctions waivers increased Iran’s support for terrorism, noted the senator, adding that such an agreement will also provide a lifeline for Russia during its aggression against Ukraine.

There is a fundamental conflict between the president’s approach to Iran and US national security interests with partners in Israel and the Middle East.

According to Risch, it is better to leave the negotiations table instead of getting confused while sitting at it.

Israel and Gulf states have expressed their sincere interest in building new security relations to protect themselves against the Iranian threat.

On that matter, Risch said that the Biden administration must indulge in these efforts.

Positions of this kind are not limited to Republicans. Even prominent Democratic leaders have expressed similar positions, despite their timid reservations about direct and scathing criticism of the Biden administration.

US Senator Bob Menendez, Chairman of the Senate Foreign Relations Committee, released a statement in advance of Biden’s trip to Israel, the West Bank, and Saudi Arabia.

“President Biden’s visit to Israel, the West Bank, and the Kingdom of Saudi Arabia should underscore that the United States has not walked back its commitment to the region, and in fact will continue to lead with diplomacy and convene partners around a common vision,” the statement read.

“It should unite regional actors as a strong counter-weight to an Iran intent on bolstering its nuclear capabilities and menacing its neighbors,” it added.



Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation
TT

Hevolution CEO Discusses Career in Innovation, Medicine, and Business

Dr. Mehmood Khan, CEO of the Hevolution Foundation
Dr. Mehmood Khan, CEO of the Hevolution Foundation

Dr. Mehmood Khan, CEO of the Hevolution Foundation, the largest philanthropy organization funding aging medicine in the world, expressed that receiving Saudi citizenship will boost his scientific and practical capabilities.
He said this new status will help him advance his research, especially in addressing aging.
This comes as part of a recent royal decree granting Saudi citizenship to several notable scholars, doctors, researchers, and innovators.
“Our Chairman, his Royal Highness (Crown Prince Mohammed bin Salman), has very high expectations of our work and the impact we need to do; We were created in part because of his vision,” Khan told Asharq Al-Awsat.
“Living up to the expectations and challenges we get faced with is itself exciting, but it is challenging,” revealed Khan, affirming that Hevolution’s team is “up to that task.”
Khan, who has experience in both corporate and medical fields, told Asharq Al-Awsat that his work across academic, public, and private sectors has been a continuous learning process, with each area enhancing the others.
According to the CEO, these industries are interconnected, and combining their strengths often leads to the best solutions.
This insight inspired the Hevolution initiative, which brings together the scientific community, NGOs, pharmaceutical companies, policymakers, academia, biotech firms, CEOs, and others to promote healthy aging.
Khan highlighted the value of integrating insights from different sectors.
Academia provides detailed research, the public sector offers insights on population health and regulations, and the corporate world brings innovation and efficiency, explained Khan, adding that by merging these perspectives, the world can tackle complex health challenges more effectively.
“We’ve been working through, and are now investing, funding and partnering with over 200 scientists around the world, and over 150 different university labs,” said Khan.
Hevolution uses this integrated approach to advance healthy aging.
This initiative embodies my passion for addressing major challenges and offers a significant opportunity to make a global impact.
Khan talked about the first $400 million commitment Hevolution made in the last 23 months, calling it “unprecedented.”
“There has never been a non-profit organization in the world that has gone from not existing to now becoming the largest philanthropy funding aging biology and medicine in the world,” affirmed Khan.
Khan stressed that work at Hevolution not only pushes scientific boundaries but also promotes cross-sector collaboration to improve global health outcomes.
Since Khan’s early days in medical school, he’s been deeply interested in nutrition and population health, which was an unconventional focus back then. This journey set the foundation for his later work in community health.
Khan’s time as an endocrinology faculty member at the Mayo Clinic was crucial. He led programs on diabetes, endocrine diseases, metabolism, and nutrition, which strengthened his expertise in designing disease prevention systems.
In the private sector, Khan took on a key role at Takeda Pharmaceutical as the global head of R&D, which shaped his approach to innovative healthcare solutions.
At PepsiCo, as Chief Scientific Officer, he learned crucial principles of scale, impact, transformation, and tackling global challenges.
As CEO of Hevolution, Khan uses all his professional experience to advance the foundation’s mission of developing health sciences to address age-related diseases.
Khan serves on the boards of Reckitt Benckiser and the Saudi Research, Development, and Innovation Authority (RDIA).
He is the CEO of Life Biosciences, a member of Saudi Arabia’s biotechnology strategy committee, and the chair of the advanced technology visiting committee at the US National Institute of Standards and Technology (NIST).
Khan told Asharq Al-Awsat that he feels honored to have recently become a Saudi citizen by royal decree, while also holding dual US and UK citizenship. This helps him lead Hevolution effectively and work closely with international partners.
Khan commented on his recent Saudi citizenship, saying that in addition to feeling honored to receive Saudi citizenship by royal decree, alongside other distinguished individuals, this recognition is a great privilege.
Being a Saudi citizen, as per Khan, is a significant milestone and acknowledges the progress in his work in aging science and global health. It also strengthens Khan’s commitment to the work at Hevolution.
Khan noted that this new status enhances his ability to build relationships and collaborate within the Kingdom and internationally. It offers a deeper connection with the local community and better opportunities to engage with policymakers and leaders.
He also said that this recognition boosts Hevolution’s global presence and credibility, making the foundation’s collaborations with international scientists and business leaders stronger. It positions Hevolution as a key player in addressing age-related diseases.
Khan emphasized that this honor reflects the hard work and innovation of Hevolution’s entire team.
The CEO said that it was collective efforts that have made this achievement possible.
Khan also said he is excited to engage more deeply with the scientific and medical community in the Kingdom, adding that his new citizenship helps him contribute to Vision 2030 and the national biotechnology strategy, promoting innovation and attracting top global talent.